Compare AYTU & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | RLYB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 28.7M |
| IPO Year | 2015 | 2021 |
| Metric | AYTU | RLYB |
|---|---|---|
| Price | $2.63 | $8.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | 45.8K | ★ 250.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,632,080.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 277.47 | 43.00 |
| 52 Week Low | $0.95 | $0.22 |
| 52 Week High | $3.07 | $11.49 |
| Indicator | AYTU | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 50.51 |
| Support Level | $2.14 | $0.48 |
| Resistance Level | $2.66 | $11.49 |
| Average True Range (ATR) | 0.10 | 0.68 |
| MACD | 0.00 | -0.45 |
| Stochastic Oscillator | 60.87 | 2.97 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.